Holen Sie sich die Stockscreener-App
0.484
1.87%
0.0089
Handel nachbörslich:
.46
-0.024
-4.96%
Schlusskurs vom Vortag:
$0.4751
Offen:
$0.499
24-Stunden-Volumen:
415.13K
Relative Volume:
0.25
Marktkapitalisierung:
$4.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.38M
KGV:
-0.0187
EPS:
-25.91
Netto-Cashflow:
$-12.72M
1W Leistung:
-19.33%
1M Leistung:
-47.01%
6M Leistung:
-89.22%
1J Leistung:
-48.51%
1-Tages-Spanne:
$0.46
$0.50
1-Wochen-Bereich:
$0.4515
$0.62
52-Wochen-Spanne:
$0.2654
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Firmenname
Windtree Therapeutics Inc
Sektor
Branche
Telefon
(215) 488-9300
Adresse
2600 KELLY ROAD, WARRINGTON, PA
Vergleichen Sie WINT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| WINT | 0.484 | 4.20M | 0 | -11.38M | -12.72M | -25.91 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-26 | Eingeleitet | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Aktie (WINT) Neueste Nachrichten
Windtree Therapeutics CEO to retire with company's future in doubt - The Business Journals
Leadership Transition at Windtree Therapeutics: Fraser Retires, Latkin Takes Helm - MyChesCo
Windtree Therapeutics Announces CEO Transition and Appointment of New Chief Executive Officer - Defense World
ARMISTICE CAPITAL, LLC Acquires New Stake in Windtree Therapeuti - GuruFocus.com
Windtree Therapeutics Appoints Jed Latkin as New CEO - TipRanks
Windtree Therapeutics announces CEO Fraser to retire, Latkin to succeed - TipRanks
Windtree Therapeutics announces CEO transition - Investing.com
Windtree Announces Leadership Transition Plan With Industry Veterans - GlobeNewswire
Windtree Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2024 - Marketscreener.com
WINT Stock Hits 52-Week Low at $0.53 Amid Steep Decline - Investing.com
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands - Yahoo Finance
Windtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure Treatment - MSN
WINT stock touches 52-week low at $0.62 amid sharp annual decline - Investing.com
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock - MSN
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong - GlobeNewswire
Windtree Therapeutics Initiates SEISMiC C Study of - GlobeNewswire
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 - The Manila Times
Windtree Therapeutics Secures Global Patent Filings for Istaroxime - MSN
Windtree Therapeutics announces $27.24 million equity sale option - Investing.com India
Windtree Therapeutics announces $27.24 million equity sale option By Investing.com - Investing.com UK
Windtree Therapeutics Prepares to Highlight Istaroxime Progress at ThinkEquity Conference - MSN
Windtree Therapeutics completes national phase filings for istaroxime - Yahoo Finance
Windtree Therapeutics advances global patent filings for shock therapy - Investing.com
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewswire
Windtree To Present at the ThinkEquity Conference on October 30th - GlobeNewswire
Reviewing Windtree Therapeutics (NASDAQ:WINT) and INmune Bio (NASDAQ:INMB) - Defense World
Windtree Therapeutics Secures Patent for Heart Failure Treatment in Japan - MSN
Windtree Therapeutics secures Japan patent for heart drug - Investing.com
Windtree Therapeutics secures Japan patent for heart drug By Investing.com - Investing.com Australia
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - The Manila Times
A significant driver of top-line growth: Windtree Therapeutics Inc (WINT) - SETE News
Windtree Therapeutics Inc (WINT) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Recent Insider Activity Suggests Potential Gains for Windtree Therapeutics Inc (WINT) - Knox Daily
Was Windtree Therapeutics Inc (WINT)’s session last reading good? - US Post News
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones - Research Tree
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MSN
Ladenburg Thalmann slashes price target on Windtree Therapeutics Inc [WINT] – find out why. - The DBT News
Windtree Therapeutics CEO buys $4.9k in company stock - Investing.com India
Windtree Therapeutics advances Phase 2b cardiogenic shock study By Investing.com - Investing.com Australia
Windtree Therapeutics CEO buys $4.9k in company stock By Investing.com - Investing.com Australia
WINT’s Stock Journey: What Investors Need to Know About Windtree Therapeutics Inc’s Performance - The InvestChronicle
Windtree Therapeutics advances Phase 2b cardiogenic shock study - Investing.com India
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - The Manila Times
Finanzdaten der Windtree Therapeutics Inc-Aktie (WINT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):